Skip to main content

Anti-N-methyl-D-Aspartate Receptor (NMDAR), Spinal Fluid

CPT 86255
Synonyms
  • Autoimmune Dementia Panel Spinal Fluid
  • Paraneoplastic

Test Details

Methodology

Immunofluorescence, Immunoblot

Result Turnaround Time

4 days

Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Use

NMDAR1 is a glutamate receptor and ion channel found in neurons. This receptor is thought to be very important for controlling synaptic plasticity and mediating learning and memory functions. Antibodies against NMDAR1 generate both neurologic and psychiatric symptoms. Common symptoms include personality change, psychosis, abnormal movements, seizures and autonomic dysfunction. Anti-NMDA receptor IgG antibody is found in a subset of patients with autoimmune limbic encephalitis and may occur with or without associated tumor. Decreasing antibody levels may be associated with therapeutic response; therefore, clinical correlation must be strongly considered. A negative test result does not rule out a diagnosis of autoimmune limbic encephalitis.

Special Instructions

If reflex test is performed, additional charges/CPT code(s) may apply.

Limitations

This test was developed and its performance characteristics determined by Labcorp in accordance with CLIA requirements. This test has not been cleared or approved by the Food and Drug Administration.

Custom Additional Information

Anti-NMDAR1 encephalitis represents one of the most frequent causes of autoimmune encephalitis. This type of encephalitis may also be associated with post-COVID-19 related neurological symptoms.

Specimen Requirements

Specimen

Cerebrospinal fluid (CSF)

Volume

2 mL

Minimum Volume

1 mL

Container

Sterile plastic tube

Stability Requirements

Temperature

Period

Room temperature

14 days

Refrigerated

14 days

Frozen

14 days

Freeze/thaw cycles

Stable x3

Storage Instructions

Room temperature

Causes for Rejection

Gross hemolysis; grossly lipemic; gross icterus

References

Lynch DR, Rattelle A, Dong YN, Hoslin K, Gleichman AJ, Panzer JA. Anti-NMDA Receptor Encephalitis: Clinical Features and Basic Mechanisms. Adv Pharmacol. 2018;82:235-260.29413523
Miya K, Takahashi Y, Mori H. Anti-NMDAR autoimmune encephalitis. Brain Dev. 2014 Sep;36(8):645-652.24211006
Scheer S, John RM. Anti-N-Methyl-D-Aspartate Receptor Encephalitis in children and Adolescents. J Pediatr Health Care. 2016 Jul-Aug:30(4):347-358.26507948
Venkatesan A, Adatia K. Anti-NMDA-Receptor Encephalitis: From Bench to Clinic. ASC Chem Neurosci. 2017 Dec 20;8(12):2586-2595.29077387
Zandifar A, Badrfam R. COVID-19 and anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis: Are we facing an increase in the prevalence of autoimmune encephalitis? J Med Virol. 2021 Apr;93(4):1913-1914.33336825

LOINC® Map

Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
505720 Anti-NMDAR, Spinal Fluid 82988-7 505599 NMDAR Antibody, Cell-based IFA 82988-7
Order Code505720
Order Code NameAnti-NMDAR, Spinal Fluid
Order Loinc82988-7
Result Code505599
Result Code NameNMDAR Antibody, Cell-based IFA
UofM
Result LOINC82988-7
Reflex Table for NMDAR Antibody, Cell-based IFA
Order Code Order Name Result Code Result Name UofM Result LOINC
Reflex 1 505606 Anti-NMDAR Antibody Titer 505606 Anti-NMDAR Antibody Titer 90840-0
Reflex 1
Order Code505606
Order NameAnti-NMDAR Antibody Titer
Result Code505606
Result NameAnti-NMDAR Antibody Titer
UofM
Result LOINC90840-0